Ann: Final Antibody Selection Complete, page-30

Worth noting that Cologuard is a liquid biopsy test which is used for patients with previous colorectal ca. Unlike ColoSTAT it’s not a first time diagnositic test. Good marketing idea and I’m sure the team are all over the commercialisation side of things. No new news so I’m surprised at the sudden excitement. They have always been on track with development but let’s not forget that there are still 2 clinical trials ahead before Rhy can seek international approvals. Really this stock should be in the .30s at the moment - considering progress, on time and on budget, which amounts to a lot of derisking since listing - but the market is a strange beast...